The drug pipeline of Priavoid is composed of 6 compounds in development with 5 CNS diseases:

  • Alzheimer’s disease
  • Amyotrophic lateral sclerosis
  • Tauopathies
  • Huntington’s disease
  • Parkinson’s disease



Our current focus is on Phase II clinical trial of PRI-002, a synthetic all-D-peptide for causal treatment of Alzheimer’s disease.


Thus, PRI-002 has three unique selling propositions (USPs):


New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Intervention Strategy

Priavoid follows a completely new strategy for treatment of Alzheimer’s disease.

We have developed stable D-peptides that are able to overcome the blood-brain barrier, do not interfere with formation or clearance with normal non-toxic Abeta monomers, but specifically eliminate cytotoxic Abeta oligomers.


Partnering is a key component of Priavoids strategy